Medical laser maker Lumenis (Yokneam, Israel) has received FDA clearance for its ResurFX fractional non-ablative laser module. ResurFX is an application module for the company's M22 platform, expanding its capabilities to perform fractional non-ablative skin resurfacing, a fast-growing, minimally invasive procedure.
Related: Lumenis debuts fractional non-ablative laser module for common skin disorders
ResurFX uses a 1565 nm fiber laser and the company's CoolScan scanner technology, which enables a homogeneous, uniform pattern of coagulation columns in one pass to help protect the patient's skin, the company claims. The scanner also allows a choice between more than 600 combinations of shape, size, and density, A proprietary algorithm places each fractional spot in a controlled, non-sequential manner, allowing the tissue to relax between pulses and providing protection from overheating.
ResurFX will be one of of the company's products featured at the 5-Continent Congress (5CC), which will take place from September 18-21, 2013, in Cannes, France.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Subscribe now to BioOptics World magazine; it's free!